Research on dyslipidaemias in 2017 reaffirmed the central role of reducing the levels of atherogenic apolipoprotein B-containing lipoproteins, predominantly LDL, in preventing ischaemic cardiovascular events. However, whether increasing HDL-cholesterol levels in isolation can reduce cardiovascular risk remains to be determined.

Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targets / A.L. Catapano. - In: NATURE REVIEWS. CARDIOLOGY. - ISSN 1759-5002. - 15:2(2018 Feb), pp. 75-76. [10.1038/nrcardio.2017.221]

Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targets

A.L. Catapano
2018

Abstract

Research on dyslipidaemias in 2017 reaffirmed the central role of reducing the levels of atherogenic apolipoprotein B-containing lipoproteins, predominantly LDL, in preventing ischaemic cardiovascular events. However, whether increasing HDL-cholesterol levels in isolation can reduce cardiovascular risk remains to be determined.
cardiology and cardiovascular medicine
Settore BIO/14 - Farmacologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
2018-Nat Rev Cardiol-Submitted.pdf

accesso riservato

Tipologia: Pre-print (manoscritto inviato all'editore)
Dimensione 899.16 kB
Formato Adobe PDF
899.16 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/582820
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact